Iterative Design and in Vivo Evaluation of an Oncolytic Antilymphoma Peptide
J Johannes Eksteen1, Dominik Ausbacher, Jaione Simon-Santamaria
1Lytix Biopharma AS , P.O. Box 6447, Siva Innovation Centre Tromsø, Tromsø NO-9294, Norway.
Abstract:
Oncolytic peptides represent a promising new strategy within the field of cancer immunotherapy. Here we describe the systematic design and evaluation of short antilymphoma peptides within this paradigm. The peptides were tested in vitro and in vivo to identify a lead compound for further evaluation as novel oncolytic immunotherapeutic. In vitro tests revealed peptides with high activity against several lymphoma types and low cytotoxicity toward normal cells. Treated lymphoma cells exhibited a reduced mitochondrial membrane potential that resulted in an irreversible disintegration of their plasma membranes. No caspase activation or ultrastructural features of apoptotic cell death were observed. One of these peptides, 11, was shown to induce complete tumor regression and protective immunity following intralesional treatment of murine A20 B-lymphomas. Due to its selectivity for lymphoma cells and its ability to induce tumor-specific immune responses, 11 has the potential to be used in intralesional treatment of accessible lymphoma tumors.
Insights
Researchers developed novel oncolytic peptides for cancer immunotherapy. Peptide 11 effectively eliminated lymphoma tumors and stimulated protective immunity, showing potential for treating accessible lymphoma tumors.
Area of Science:
- Oncology
- Immunotherapy
- Peptide Therapeutics
Background:
- Oncolytic peptides are an emerging strategy in cancer immunotherapy.
- Developing targeted therapies for lymphoma remains a critical challenge.
Purpose of the Study:
- To design and evaluate short antilymphoma peptides for oncolytic immunotherapy.
- To identify a lead peptide compound with high efficacy and selectivity against lymphoma cells.
Main Methods:
- Systematic design and in vitro/in vivo evaluation of antilymphoma peptides.
- Assessment of cytotoxicity, mitochondrial membrane potential, and cell death pathways.
- Intralesional treatment of murine A20 B-lymphomas with lead peptide.
Main Results:
- Several peptides demonstrated high activity against lymphoma cells with low toxicity to normal cells.
- Peptide 11 induced lymphoma cell death via plasma membrane disintegration, independent of apoptosis.
- Peptide 11 achieved complete tumor regression and induced protective immunity in a murine lymphoma model.
Conclusions:
- Peptide 11 is a promising candidate for oncolytic immunotherapy against lymphoma.
- Its selectivity and ability to induce immune responses support its potential for intralesional treatment of accessible lymphoma tumors.
